NASDAQ:ALXN
Delisted
Alexion Pharmaceuticals Stock News
$182.50
+0 (+0%)
At Close: May 27, 2022
3 Reasons AstraZeneca's Merger With Alexion Will Work for Investors
06:34am, Wednesday, 16'th Dec 2020
Here's why AstraZeneca's shareholders can expect healthy returns from this $39 billion investment.
ALEXION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of ALXN and Encourages Investors to Contact the Firm
07:45pm, Tuesday, 15'th Dec 2020
NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Alexion Ph
ETFs to Tap AstraZeneca Mega-Deal to Buy Alexion
11:17am, Tuesday, 15'th Dec 2020
AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.
AstraZeneca stock price falls sharply on a $39 billion bill to buy Alexion
10:39am, Tuesday, 15'th Dec 2020
Investors don't seem impressed with AstraZeneca's (LON: AZN) latest deal, which is also the biggest deal in the company's history. Fundamental analysis: Hefty price paid The British-Swedish pharma g
AstraZeneca PLC (AZN) AstraZeneca to acquire Alexion Conference Call (Transcript)
09:50am, Tuesday, 15'th Dec 2020
Seeking Alpha Transcripts | Healthcare AstraZeneca PLC (AZN) AstraZeneca to acquire Alexion Conference Call (Transcript) Dec. 15, 2020 9:50 AM ET | | About: AstraZeneca PLC (AZN), AZNCF by: SA Transcr
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Alexion Pharmaceuticals, Inc. Buyout
06:20pm, Monday, 14'th Dec 2020
WILMINGTON, Del., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Alexion Pharmaceuticals, Inc. (“Alexion”) (NASDAQ GS: ALXN) regarding possible breache
SHAREHOLDER ALERT: WeissLaw LLP Investigates Alexion Pharmaceuticals, Inc.
04:05pm, Monday, 14'th Dec 2020
NEW YORK, Dec. 14, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alexion Pharmaceuticals, Inc. ("Alexi
Biotech ETFs surge on vaccine rollout, Alexion-AstraZeneca tie-up
02:35pm, Monday, 14'th Dec 2020
Biotech exchange-traded funds rallied Monday as the rollout of the coronavirus vaccine across America shed a bullish light on the industry. The First Trust NYSE Arca Biotechnology Index Fund jumped 4%
Alexion Lifts Nasdaq on Buyout News; PayPal Gets Bitcoin Boost
01:07pm, Monday, 14'th Dec 2020
The Nasdaq Composite looked to get back into record territory on Monday.
Alexion (ALXN) to Be Acquired by AstraZeneca for $39 Billion
12:10pm, Monday, 14'th Dec 2020
Alexion (ALXN) is set to be acquired by AstraZeneca for $39 billion or $175 per share. The acquisition is expected to close in the third quarter of 2021.
AstraZeneca: Starting The Acquisition Boom
12:06pm, Monday, 14'th Dec 2020
Over the weekend, AstraZeneca made a $39 billion offer to acquire Alexion Pharmaceuticals in a deal that looks like it will benefit both parties.
Why Alexion Pharmaceuticals Is Soaring and AstraZeneca Is Sinking Today
11:35am, Monday, 14'th Dec 2020
Alexion finally gets taken out.
What This Alexion Acquisition Means for AstraZeneca
11:27am, Monday, 14'th Dec 2020
Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) shares shot up on Monday after it was announced over the weekend that the company would be acquired by AstraZeneca PLC (NASDAQ: AZN).
Why AstraZeneca Wants To Buy Alexion Pharmaceuticals
11:13am, Monday, 14'th Dec 2020
Late last week, AstraZeneca said that it would acquire Alexion Pharmaceuticals - a company best known for its Soliris and Ultomiris drugs - in a cash and stock deal valued at about $39 billion. There
AstraZeneca to buy Alexion Pharmaceuticals in $39 billion deal
10:42am, Monday, 14'th Dec 2020
AstraZeneca is buying Alexion Pharmaceuticals for $39 billion in stock and cash, its largest deal ever. The transaction values Alexion at $175 a share, a 40% premium over its average price in the past